Text

STOP WASTING MONEY

ON UNNECESSARY MUSCULOSKELETAL CARE AND SURGERY. REDUCE COST, INCREASE PRODUCTIVITY, IMPROVE EMPLOYEE SATISFACTION.

N1cause

TACKLING THE #1 CAUSE OF MISSED WORKDAYS

EMPLOYEES LOSE AN AVERAGE OF 10 WORKDAYS YEARLY TO MUSCULOSKELETAL PAIN,1 WITH ADDED COSTS FROM SURGERIES, THERAPY, AND TREATMENTS.

Apos® provides a non-invasive solution to restore mobility, reduce pain, and support a healthier, more productive workforce.

A GAME-CHANGER FOR EMPLOYERS

  • Over 3:1 ROI within the first year of implementation2
  • Significant reductions in the need for surgeries and injections2
  • Up to 89% reduction in elective total knee surgeries3
  • Average savings of $3,689 per patient2
Contact Us

APOS® IS PRECISION MEDICINE FOR MUSCULOSKELETAL PAIN

A targeted innovative approach to addressing knee osteoarthritis, chronic hip and non-specific back pain. By considering each patient’s unique anatomy, biomechanics, neuromuscular responses, and medical history, Apos® delivers personalized treatment tailored to individual needs. As easy to use as wearing a pair of glasses, it significantly improves pain relief, functional ability, and quality of life.

CARE THAT EMPLOYEES WANT

After treating over 150,000 patients and 15 years of research and development, the results of Apos® speak for themselves.

AFTER TREATMENT, APOS® PATIENTS…

HAVE​

60
%

BETTER FUNCTION1
(ON AVERAGE)

EXPERIENCE​

70
%

LESS PAIN1
(ON AVERAGE)​

REPORT A

96
%

SATISFACTION
RATE2

CAN WALK​

13
%

FASTER3

USE

58
%

LESS
PAINKILLERS4

BENEFITS TO EMPLOYERS

  • IMPROVED RETENTION
    Reduced absenteeism and improved well-being lead to more productive employees and higher retention rates.
  • ONGOING COST SAVINGS
    A recent study showed 43% reduction in MSK management costs within one year5 of implementation.
  • EASY IMPLEMENTATION
    Seamless integration with minimal management from benefits administrators.
Contact Us

BY OFFERING APOS®, YOU’RE PROVIDING A SCIENTIFICALLY PROVEN, EASY-TO-IMPLEMENT SOLUTION THAT IMPROVES BOTH EMPLOYEE WELL-BEING AND FINANCIAL OUTCOMES.

heart lady

WHAT OUR PATIENTS SAY

“THE FIRST DAY I TRIED THEM, I CRIED—BECAUSE I COULD WALK NORMALLY AGAIN.”

​- ROBERT L.​
FORMER MARATHON RUNNER WITH CHRONIC KNEE PAIN​

“NOW I CAN JOG AS FAST AS I WOULD NORMALLY JOG.”

​- GEORGE T.
​FDNY EMPLOYEE WHO HAD CHRONIC BACK PAIN​

“THANKS TO APOS® I’M ABLE TO RIDE HORSES, SKI, AND DANCE AGAIN.”​

– JONQUILLE S.​
BROKE FEMUR BONE IN HORSE-RIDING ACCIDENT​

CHOOSE AN MSK SOLUTION THAT’S MEANINGFUL FOR YOU AND YOUR EMPLOYEES

CONTACT US TO IMPROVE YOUR MSK RESULTS WHILE REDUCING COSTS

FAQs

Apos® reduces the need for expensive surgeries, injections, and treatments while improving employee health, leading to fewer missed workdays and higher productivity. A recent study showed 43% reduction in MSK management costs within one year of implementation.

Unlike traditional approaches, Apos® uses advanced gait science to retrain how patients walk, addressing both the symptoms and underlying causes of pain—all from the comfort of home or the office.

Our approach is backed by over 70 peer-reviewed clinical publications, including a recent study showing that 89% of eligible total knee replacement patients avoided surgery for up to 6 years with Apos®.4

Apos® is FDA cleared for treating knee osteoarthritis and FDA-registered and evidence-backed for chronic hip pain and non-specific lower back pain, offering personalized treatment for each patient’s needs.

Many feel relief right away as the device helps realign their joints. For others, it may take 3-6 months. Long-term relief happens because, over time, the muscles learn to stabilize the joints better, even when they are not wearing the device.2

Yes, studies show that Apos® can reduce the need for total knee replacement surgery by up to 89%.

SOURCES

  1. Link to article
  2. J Health Econ Outcomes Res. 2024 May 16;11(1):134-140. doi: 10.36469/001c.117155. eCollection 2024.
  3. Benn R, Rawson L, Phillips A. Utilising a non-surgical intervention in the knee osteoarthritis care pathway: a 6-year retrospective audit on NHS patients. Therapeutic Advances in Musculoskeletal Disease. 2023;15.
  4. Reichenbach et al., JAMA (2020): 70% pain reduction with Apos® vs. 35% in controls.
  5. Mark J, Shema-Shiratzky S, Sommer J, Nolan T, Segal G. Reduction in Healthcare Resource Utilization Following Treatment With a Home-Based Footworn Device in Patients With Knee Osteoarthritis: A Retrospective Claims Analysis. J Health Econ Outcomes Res. 2024 May 16;11(1):134-140. doi: 10.36469/001c.117155. PMID: 38765914; PMCID: PMC11102045.
  6. Sorin, A., et al. (2020). BMC Musculoskelet Disord. 21:846.
  7. Bar-Ziv Y, et al. (2010). BMC Musculoskelet Disord. 11:179.